Anti-depressants and centrally active agents for fibromyalgia syndrome

Cochrane Database of Systematic Reviews

Volumn , Issue 4, 2006, Pages

  Nishishinya, María Betina ^a   Walitt, B ^b   Urrutia, G ^b   Mease, P ^b   Rodriguez, A ^b   Riera, R ^b   Gonzalez, L ^b   Darko, G ^b  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; AMOXAPINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; CENTRAL MUSCLE RELAXANT; CITALOPRAM; CLOMIPRAMINE; CYCLOBENZAPRINE; DESIPRAMINE; DOSULEPIN; DOXEPIN; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE MALEATE; GABAPENTIN; IMIPRAMINE; MILNACIPRAN; MOCLOBEMIDE; NEFAZODONE; NORTRIPTYLINE; PAROXETINE; PIRLINDOLE; PLACEBO; PROTRIPTYLINE; SERTRALINE; TRAZODONE; TRIMIPRAMINE; UNINDEXED DRUG; VENLAFAXINE;

CLINICAL TRIAL; COMPARATIVE STUDY; DRUG EFFICACY; DRUG SAFETY; FIBROMYALGIA; HUMAN; OUTCOME ASSESSMENT; PHYSIOTHERAPY; QUALITY CONTROL; REVIEW; TREATMENT OUTCOME;

EID: 37649029802     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006192     Document Type: Review

References (25)

1. Arnold LM, Keck PE Jr, Welge JA. Antidepressant treatment of fibromyalgia. A meta-analysis and review. Psychosomatics 2000;41: 104-13.
2. Bartels EM, Danneskiold-Samsoe B. Histological abnormalities in muscle from patients with certain types fibrositis. Lancet 1986;1: 755-7.
3. Bengtsson A, Henriksson KG, Larsson J. Muscle biopsy in primary fibromyalgia. Light-microscopical and histochemical findings. Scandinavian Journal of Rheumatology 1986;15:1-6.
4. Bradley LA, Alberts KR, Alarcón GS, Alexander MT, Mountz JM, Weigent DA, et al. Abnormal brain regional cerebral blood ow (rCBF) and cerebrospinal fluid (CSF) levels of substance P (SP) in patients and non-patients with fibromyalgia (FM). Arthritis and Rheumatism 1996;39(9 Suppl):S212.
5. Cathebras P, Lauwers A, Rousset H. Fibromyalgia. A critical review. Annales de Médecine Interne 1998;149(7):406-14.
6. Crofford LJ, Pillimer SR, Kalogeras KT, Cash JM, Michelson D, Kling MA, et al. Hypothalamic-pituitary-adrenal axis perturbations in patients with fibromyalgia. Arthritis and Rheumatism 1994;37: 1583-92.
7. Hawley DJ, Wolfe F, Cathey MA. Pain, functional disability, and psychological status: a 12-month study of severity in fibromyalgia. The Journal of Rheumatology 1988;15:1551-6.
8. Hawley DJ, Wolfe F. Pain, disability, and pain/disability relationships in seven rheumatic disorders: a study of 1,522 patients. The Journal of Rheumatology 1991;18:1552-7.
9. Higgins JPT, Green S, editors. Assessment of study quality. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 (updated May 2005). In: The Cochrane Library, Issue 3, 2005.
10. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clinical Trials 1996;17(1):1-12.
11. Lawrence RC, Helmick CG, Arnett FC, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis and Rheumatism 1998;41(5):778-99.
12. Lund N, Bengtsson A, Thorborg P. Muscle tissue oxygen pressure in primary fibromyalgia. Scandinavian Journal of Rheumatology 1986; 15:165-73.
13. Mease PJ. Fibromyalgia syndrome: Review of clinical presentation, pathogenesis, outcome measures, and treatment. The Journal of Rheumatology 2005;75:6-21.
14. Moldofky H. Sleep-wake mechanism in fibrositis. The Journal of Rheumatology 1989;16(Suppl):47-8.
15. O'Malley PG, Balden E, Tomkins G, Santoro J, Kroenke K, Jackson JL. Treatment of fibromyalgia with antidepressants: a meta-analysis. Journal of General Internal Medicine 2000;15(9):659-66.
16. Mease PJ, Clauw DJ, Arnold LM, et al. Fibromyalgia syndrome. The Journal of Rheumatology 2005;32(11):2270-7.
17. Smith WA. Fibromyalgia Syndrome. The Nursing Clinics of North America 1998;33(4):653-69.
18. Smythe HA: Fibrositis, other diffuse musculoskeletal syndromes. Textbook of Reumathology, First edition. Edited by WN Kelley, ED Harris Jr, S Ruddy, CB Sledge. Fibrositis and other diffuse musculoskeletal syndromes, Textbook of Reumathology, First edition. Edited by WN Kelley, ED Harris Jr, S Ruddy, CB Sledge. Philadelphia, WB Saunders, 1981, pp485-493.
19. Tugwell P, Shea B, Boers M, Brooks P, Simon L, Strand V, Wells G (editors). Evidence-based Rheumatology. London: BMJ Publishing Group, 2004.
20. Vaeroy H, Helle R, Forre Ø, Kåss, Terenius L. Elevated CSF levels of substance P and high incidence of Raynaud phenomenon in patients with fibromyalgia: new features for diagnosis. Pain 1988;33:21-6.
21. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, Tugwell P, Campbell SM, Abeles M, Clark P, et al. The American College of Rheumatology 1990 Criteria, for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis and Rheumatism 1990;33(12):1863-4.
22. Wolfe F, Anderson J, Harkness D, Bennett RM, Caro XJ, Goldenberg DL, Russell IJ, Yunus MB. A prospective, longitudinal, multicenter study of service utilization and costs in fibromyalgia. Arthritis and Rheumatism 1997;40(9):1553-5.
23. Yunus M, Masi AT, Calabro JJ, Miller KA, Feigenbaum SL. Primary fibromyalgia (fibrositis): clinical study of 50 patients with matched normal controls. Seminars in Arthritis and Rheumatism 1981;11(1): 151-71.
24. Yunus M, Masi AT, Calabro JJ, Shah IK. Primary fibromyalgia. American Family Physician 1982;25(5):115-21.
25. Yunus MB. Primary fibromyalgia syndrome: current concepts. Comprehensive Therapy 1984;10(8):21-8.